In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.

Knappskog, Stian; Bjørnslett, Merete; Myklebust, Line M; Huijts, Petra E A; Vreeswijk, Maaike P; Edvardsen, Hege; Guo, Yongli; Zhang, Xuemei; Yang, Ming; Ylisaukko-Oja, Sanna K; Alhopuro, Pia; Arola, Johanna; Tollenaar, Rob A E M; van Asperen, Christi J; Seynaeve, Caroline; Staalesen, Vidar; Chrisanthar, Ranjan; Løkkevik, Erik; Salvesen, Helga B; Evans, D Gareth; Newman, William G; Lin, Dongxin; Aaltonen, Lauri A; Børresen-Dale, Anne-Lise; Tell, Grethe S; Stoltenberg, Camilla; Romundstad, Pål; Hveem, Kristian; Lillehaug, Johan R; Vatten, Lars; Devilee, Peter; Dørum, Anne; Lønning, Per E

Cancer cell. 2011;19(2):273-82.

Access to files

Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

Full-text held externally

Abstract

MDM2 plays a key role in modulating p53 function. The MDM2 SNP309T > G promoter polymorphism enhances Sp1 binding and has been linked to cancer risk and young age at diagnosis although with conflicting evidence. We report a second MDM2 promoter polymorphism, SNP285G > C, residing on the SNP309G allele. SNP285C occurs in Caucasians only, where 7.7% (95% CI 7.6%-7.8%) of healthy individuals carry the SNP285C/309G haplotype. In vitro analyses reveals that SNP309G enhances but SNP285C strongly reduces Sp1 promoter binding. Comparing MDM2 promoter status among different cohorts of ovarian (n = 1993) and breast (n = 1973) cancer patients versus healthy controls (n = 3646), SNP285C reduced the risk of both ovarian (OR 0.74; CI 0.58-0.94) and breast cancer (OR 0.79; CI 0.62-1.00) among SNP309G carriers.

Institutional metadata

University researcher(s):

Record metadata

Manchester eScholar ID:
uk-ac-man-scw:132929
Created by:
Newman, William
Created:
12th October, 2011, 14:36:31
Last modified by:
Newman, William
Last modified:
10th April, 2013, 20:06:53

Can we help?

The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.